JAGUAR HEALTH, INC. Warrants Not Settleable in Cash, Fair Value Disclosure
JAGUAR HEALTH, INC. (JAGX) had Warrants Not Settleable in Cash, Fair Value Disclosure of $1.00 thousand as of 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:WarrantsNotSettleableInCashFairValueDisclosure · last filed 2023-03-24
- 2022-03-31: Warrants Not Settleable in Cash, Fair Value Disclosure $1.00K.
- 2021-12-31: Warrants Not Settleable in Cash, Fair Value Disclosure $1.00K.
- 2021-09-30: Warrants Not Settleable in Cash, Fair Value Disclosure $3.00K.
- 2021-06-30: Warrants Not Settleable in Cash, Fair Value Disclosure $7.00K.
| Period end | Warrants Not Settleable in Cash, Fair Value Disclosure |
|---|---|
| 2022-03-31 | $1.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.00K 10-K · filed 2023-03-24 |
| 2021-09-30 | $3.00K 10-Q · filed 2021-11-17 |
| 2021-06-30 | $7.00K 10-Q · filed 2021-08-13 |
| 2021-03-31 | $12.00K 10-Q · filed 2021-05-17 |
| 2020-12-31 | $179.00K 10-Q · filed 2021-11-17 |
| 2019-07-23 | $4.30M 10-Q · filed 2021-11-17 |
| 2014-08-31 | $114.30K 10-K · filed 2017-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |